drugset / Trial / NCT01323985

SAP Depleter Dose Escalation Study in Healthy Volunteers

NCT01323985

Phase 1 Completed 21 enrolled GlaxoSmithKline
RandomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to provide safety information and to define the optimal induction and short term maintenance regimen for GSK2315698 to deplete circulating SAP in healthy volunteers prior to assessing in patients

Timeline

Start
2011-01-06
Primary completion
2011-06-30
Completion
2011-06-30

Drugs

EvaluationDrugModalityDoseRoute
Subject miridesap Small molecule 5 mg Intravenous
Subject miridesap Small molecule 400 mg Intravenous

Indications